A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)
This study has been withdrawn prior to enrollment.
(sponsor withdrew funding prior to patient enrollment)
Sponsor:
Massachusetts General Hospital
Collaborators:
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center
North Shore Medical Center
Sanofi
Information provided by (Responsible Party):
Rachel P. Rosovsky, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00916669
First received: June 5, 2009
Last updated: May 7, 2013
Last verified: July 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
| Study Status: | This study has been withdrawn prior to enrollment. |
|---|---|
| Estimated Study Completion Date: | No date given |
| Estimated Primary Completion Date: | July 2010 (Final data collection date for primary outcome measure) |